Cidara Therapeutics Inc. (NASDAQ:CDTX) has a beta value of 1.38 and has seen 2.86 million shares traded in the last trading session. The company, currently valued at $109.53M, closed the last trade at $0.93 per share which meant it gained $0.15 on the day or 18.49% during that session. The CDTX stock price is -72.04% off its 52-week high price of $1.60 and 56.99% above the 52-week low of $0.40. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.76 million shares traded. The 3-month trading volume is 564.45K shares.
The consensus among analysts is that Cidara Therapeutics Inc. (CDTX) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $0.18.
Cidara Therapeutics Inc. (NASDAQ:CDTX) trade information
Sporting 18.49% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the CDTX stock price touched $0.93 or saw a rise of 41.88%. Year-to-date, Cidara Therapeutics Inc. shares have moved 22.72%, while the 5-day performance has seen it change -29.69%. Over the past 30 days, the shares of Cidara Therapeutics Inc. (NASDAQ:CDTX) have changed 94.94%. Short interest in the company has seen 0.41 million shares shorted with days to cover at 1.89.
Wall Street analysts have a consensus price target for the stock at $4.67, which means that the shares’ value could jump 80.09% from current levels. The projected low price target is $3.00 while the price target rests at a high of $6.00. In that case, then, we find that the current price level is -545.16% off the targeted high while a plunge would see the stock gain -222.58% from current levels.
Cidara Therapeutics Inc. (CDTX) estimates and forecasts
Figures show that Cidara Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 34.55% over the past 6 months, with this year growth rate of 64.20%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 148.60% and 23.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be 12.00%.
3 analysts offering their estimates for the company have set an average revenue estimate of $35.67 million for the current quarter. 3 have an estimated revenue figure of $6.57 million for the next quarter concluding in Dec 2022. Year-ago sales stood $7.08 million and $7.22 million respectively for this quarter and the next, and analysts expect sales will grow by 404.10% for the current quarter and -9.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 24.60% over the past 5 years.
Cidara Therapeutics Inc. is expected to release its next earnings report between March 06 and March 10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cidara Therapeutics Inc. (NASDAQ:CDTX)’s Major holders
Insiders own 11.67% of the company shares, while shares held by institutions stand at 40.57% with a share float percentage of 45.93%. Investors are also buoyed by the number of investors in a company, with Cidara Therapeutics Inc. having a total of 53 institutions that hold shares in the company. The top two institutional holders are BVF Inc. with over 6.86 million shares worth more than $3.35 million. As of Jun 29, 2022, BVF Inc. held 9.94% of shares outstanding.
The other major institutional holder is Nantahala Capital Management, LLC, with the holding of over 4.82 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $2.35 million and represent 6.98% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.60% shares in the company for having 1.8 million shares of worth $0.88 million while later fund manager owns 0.55 million shares of worth $0.27 million as of Jun 29, 2022, which makes it owner of about 0.79% of company’s outstanding stock.